Stock Quote
Biocryst Pharmaceuticals, Inc. (BCRX.O) (Consolidated Issue listed on NASDAQ Global Market)
$8.16
27 Nov 2009
-5.88%
$8.67
$8.41
1,220,067
$8.41
$8.14
$13.47
$1.06
2.79
2,890,504
BCRX.O
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Horovitz, Zola | Chairman of the Board | -- |
| Stonehouse, Jon | President, Chief Executive Officer, Director | 1,663,240 |
| Grant, Stuart | Chief Financial Officer, Senior Vice President | 942,531 |
Profile
BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company that designs, optimizes and develops drugs that block enzymes involved in cancer, viral infections and autoimmune diseases. BioCryst integrates the necessary disciplines of biology, crystallography, medicinal chemistry and computer... Full Description
Company Address
Biocryst Pharmaceuticals, Inc.
2190
Parkway Lake Drive
Birmingham AL 35244
P: +1205.4444600
F: +1205.4444640
2190
Parkway Lake Drive
Birmingham AL 35244
P: +1205.4444600
F: +1205.4444640
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Eisai Co., Ltd | ¥3,140.00 | +40.00 |
| GlaxoSmithKline plc | £1,279.00 | +7.00 |
| Roche Holding Ltd. | CHF166.60 | +1.10 |
| BCRX.O | Industry | |
|---|---|---|
| P/E(TTM) | -- | 13.11 |
| P/S(TTM) | 5.87 | 32.32 |
| ROI(TTM) | -29.74 | 2.21 |
| ROE(TTM) | -63.30 | 3.47 |
| Consensus Recommendation | Hold |
|---|---|
| EPS Est. (Current Period) | -0.25 |
| EPS Est. (Current Year) | -0.78 |
| Total Revenue | $10.55M |
| Net Income | $-10.63M |
| EPS | $-0.28 |
